October 2015 Gynecologic Trials

Principle Investigator:
Sharad Ghamande, MD

“GOG-0229O; A Randomized Phase II Study with a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer” Sponsor: National Cancer Institute (NCI)

“GOG-0264;  A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary” Sponsor: Gynecologic Oncology Group

“GOG-0275; A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia” Sponsor: Gynecologic Oncology Group

“A011106; ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study” Sponsor: Alliance for Clinical Trials in Oncology

“PM1183-C-004-14; Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)” Sponsor: Pharma Mar USA, Inc.

Written by
Allison Brown
View all articles
Written by Allison Brown

About Jagwire

Jagwire is the official source for news and stories from Augusta University and AU Health. Daily updates highlight the many ways students, faculty, staff, researchers and clinicians "bring their A games" in classrooms and clinics on four campuses in Augusta and locations across the state of Georgia. Read on for stories of innovation in education and health care, opportunities at the center of Georgia’s new cybersecurity hub, and experiential learning that blends arts and application, humanities and the health sciences. Have a story to share with Jaguar Nation? Contact the Division of Communications & Marketing.